Compare EHang Holdings Ltd - ADR (EH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Novo Nordisk A/S — how do they compare? EHang Holdings Ltd - ADR trades at $5.36 (market cap $414.87M), while Novo Nordisk A/S trades at $51.38 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 535.7× EHang Holdings Ltd - ADR's market cap, and Novo Nordisk A/S pays a 3.56% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.
| EH | NVO | |
|---|---|---|
Market Cap | $414.87M | $222.24B |
Sector | Industrials | Health |
52-Week High | $19.99 | $71.70 |
52-Week Low | $5.41 | $35.29 |
Enterprise Value | $354.54M | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $5.41, down 0.73% on the day, with technical indicators showing bearish momentum and mixed sentiment. The company reported Q1 2026 revenue of $418 million, flat year-over-year but sharply lower than the prior quarter due to delivery timing. Despite a strong gross margin of 61.53%, the company continues to post significant net losses (-$276 million in 2025) with negative ROE and ROA. Recent news highlights both operational progress in eVTOL certification and a $30 million share repurchase program announced in June 2026.
The outlook remains challenging with persistent losses and high cash burn, though analyst consensus suggests modest upside to the $6.97 price target. Key risks include execution on commercialization, competitive pressures in the air mobility sector, and reliance on financing activities to fund operations. The stock presents speculative appeal for investors betting on long-term eVTOL adoption, but requires careful risk management given the current financial profile.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
